Last update 15 May 2025

SM-V-61

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
SM-V-61
Target-
Action-
Mechanism-
Therapeutic Areas
Infectious DiseasesRespiratory DiseasesSkin and Musculoskeletal Diseases
Active Indication
Gram-Positive Bacterial InfectionsSkin and skin structure infectionsCatheter-Related Infections+ [3]
Inactive Indication-
Originator Organization
Shanghai Tangji Biotechnology Co., Ltd.
Active Organization
Shanghai Tangji Biotechnology Co., Ltd.Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with SM-V-61
CTR20244032
/ RecruitingPhase 1
一项在中国健康受试者中随机、双盲、安慰剂对照、剂量递增、单次和多次静脉输注，评价注射用SM-V-61的安全性、耐受性及药代动力学特征的 I 期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalating, single and multiple intravenous infusion Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability and pharmacokinetic characteristics of SM-V-61 for injection
100 Clinical Results associated with SM-V-61
Login to view more data
100 Translational Medicine associated with SM-V-61
Login to view more data
100 Patents (Medical) associated with SM-V-61
Login to view more data
100 Deals associated with SM-V-61
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gram-Positive Bacterial InfectionsPhase 1
China
Shanghai Tangji Biotechnology Co., Ltd.
22 Nov 2024
Gram-Positive Bacterial InfectionsPhase 1
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
22 Nov 2024
Skin and skin structure infectionsPhase 1
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
22 Nov 2024
Skin and skin structure infectionsPhase 1
China
Shanghai Tangji Biotechnology Co., Ltd.
22 Nov 2024
Catheter-Related InfectionsIND Approval
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
24 Oct 2024
Catheter-Related InfectionsIND Approval
China
Shanghai Tangji Biotechnology Co., Ltd.
24 Oct 2024
Complicated skin and skin structure infectionIND Approval
China
Shanghai Tangji Biotechnology Co., Ltd.
24 Oct 2024
Complicated skin and skin structure infectionIND Approval
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
24 Oct 2024
Hospital-acquired pneumoniaIND Approval
China
Shanghai Tangji Biotechnology Co., Ltd.
24 Oct 2024
Hospital-acquired pneumoniaIND Approval
China
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
24 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free